Insider Selling: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells 134,713 Shares of Stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the transaction, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Syros Pharmaceuticals Stock Performance

Shares of SYRS stock opened at $0.27 on Friday. The company has a market cap of $7.28 million, a price-to-earnings ratio of -0.09 and a beta of 1.59. Syros Pharmaceuticals, Inc. has a 52 week low of $0.18 and a 52 week high of $8.17. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The firm has a 50 day moving average of $1.68 and a 200-day moving average of $3.41.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the company posted ($1.35) EPS. On average, equities analysts forecast that Syros Pharmaceuticals, Inc. will post -2.94 earnings per share for the current year.

Institutional Trading of Syros Pharmaceuticals

Several large investors have recently modified their holdings of SYRS. GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. Virtu Financial LLC acquired a new stake in shares of Syros Pharmaceuticals during the 1st quarter worth approximately $64,000. Acadian Asset Management LLC acquired a new stake in Syros Pharmaceuticals in the 1st quarter valued at $91,000. Certuity LLC acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Finally, Kennedy Capital Management LLC acquired a new stake in Syros Pharmaceuticals in the 1st quarter valued at $2,166,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on SYRS shares. StockNews.com started coverage on shares of Syros Pharmaceuticals in a research report on Friday. They set a “sell” rating for the company. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Piper Sandler reissued an “overweight” rating and set a $5.00 target price (down previously from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright reissued a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.